Iron‐Based Metal‐Organic Framework MIL‐100(Fe) Regulates Keloid Scarring in a Humanized Keloid Model

Why It Matters

Keloids lack reliable, low‑recurrence treatments; a targeted nanoplatform could dramatically improve patient outcomes and open a new therapeutic class for fibrotic diseases.

Key Takeaways

• MIL‑100(Fe) nanoparticles show >90% fibroblast viability
• TGF‑β/SMAD pathway activity reduced significantly
• In vivo treatment cut keloid volume 27% in two weeks
• Selective action spares monocytes, limiting systemic toxicity

Pulse Analysis

Keloids are a chronic fibroproliferative disorder that extends beyond the original wound margin, driven by persistent activation of the TGF‑β/SMAD signaling cascade. Conventional interventions—surgical excision, corticosteroid injections, radiation—often yield high recurrence rates and can cause adverse effects, leaving clinicians with limited options. Metal‑organic frameworks (MOFs) have emerged as versatile nanocarriers because their crystalline lattices can be tuned for size, stability, and functional payload delivery. The iron‑based MIL‑100(Fe) MOF, composed of Fe(II/III) nodes and benzenetricarboxylate linkers, offers intrinsic bioactivity and magnetic responsiveness, positioning it as a candidate for direct anti‑fibrotic therapy rather than merely a drug delivery scaffold.

The recent study demonstrates that MIL‑100(Fe) nanoparticles, averaging 142 nm, are rapidly internalized by human keloid fibroblasts within two hours while preserving >90 % cell viability after 48 hours. Molecular assays reveal a pronounced down‑regulation of TGF‑β1, SMAD3, collagen I/III, and the collagen‑processing enzyme P4HA1, indicating a direct interruption of the fibrogenic loop. In a humanized mouse model, weekly intralesional injections reduced fibrous tissue volume by 27 % after two weeks, accompanied by lower fibroblast density and a shift toward anti‑inflammatory macrophage phenotypes. Compared with systemic agents, the localized MOF approach minimizes off‑target exposure and leverages the iron core’s catalytic potential to modulate oxidative stress pathways.

If translated to clinical practice, MIL‑100(Fe) could inaugurate a new class of nanotherapeutics for scar management, potentially expanding to other fibrotic conditions such as pulmonary fibrosis or liver cirrhosis. The platform’s scalability, combined with established Good Manufacturing Practice (GMP) routes for MOF synthesis, may accelerate regulatory approval pathways, especially given its demonstrated biocompatibility. Investors and biotech firms are likely to monitor this space closely, as the convergence of nanomaterials science and precision dermatology promises both therapeutic differentiation and sizable market opportunity in the $3 billion global scar‑treatment sector. Ongoing studies will need to address long‑term safety, dosing regimens, and integration with existing surgical protocols.